[HTML][HTML] First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020

…, S Behillil, S Van Der Werf, M Valette, B Lina… - …, 2020 - eurosurveillance.org
In the WHO European Region, COVID-19 surveillance was implemented 27 January 2020.
We detail the first European cases. As at 21 February, nine European countries reported 47 …

[HTML][HTML] Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

…, A Brisebarre, F Touret, C Chapon, B Hoen, B Lina… - Nature, 2020 - nature.com
Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral
drug or vaccine is yet available for the treatment of this disease 1 , 2 – 3 . Several clinical …

[HTML][HTML] SARS-CoV-2 variants and ending the COVID-19 pandemic

A Fontanet, B Autran, B Lina, MP Kieny, SSA Karim… - The Lancet, 2021 - thelancet.com
1 Royal College of Physicians. Advancing medical professionalism. London: Royal College
of Physicians, 2018. https://www. rcplondon. ac. uk/projects/outputs/advancing-medical-…

[HTML][HTML] High-resolution measurements of face-to-face contact patterns in a primary school

…, M Quaggiotto, W Van den Broeck, C Régis, B Lina… - PloS one, 2011 - journals.plos.org
Background Little quantitative information is available on the mixing patterns of children in
school environments. Describing and understanding contacts between children at school …

[HTML][HTML] Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years …

…, E Javouhey, I Karseladze, J Kubale, R Kumar, B Lina… - The Lancet, 2022 - thelancet.com
Background Respiratory syncytial virus (RSV) is the most common cause of acute lower
respiratory infection in young children. We previously estimated that in 2015, 33·1 million …

Mutations of neuraminidase implicated in neuraminidase inhibitors resistance

O Ferraris, B Lina - Journal of Clinical Virology, 2008 - Elsevier
Influenza constitutes one of the most important upper respiratory tract infections regarding
morbidity, and mortality. Prevention and treatment of influenza rely on inactivated vaccines …

Mixed respiratory virus infections

…, F Komurian-Pradel, N Richard, G Vernet, B Lina… - Journal of Clinical …, 2008 - Elsevier
Mixed respiratory viral infections are double negative common and evidence that they are
associated with severe disease is supported by some groups. This controversial observation …

[HTML][HTML] Clinical and virological data of the first cases of COVID-19 in Europe: a case series

…, D Descamps, D Malvy, JF Timsit, B Lina… - The Lancet Infectious …, 2020 - thelancet.com
Background On Dec 31, 2019, China reported a cluster of cases of pneumonia in people at
Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named severe …

[HTML][HTML] Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination

…, B Boson, T Bourlet, A Bal, M Valette, T Andrieu, B Lina… - Nature, 2021 - nature.com
Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine 1 , 2 ,
European health authorities recommended that patients under the age of 55 years who …

[HTML][HTML] Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season

A Meijer, A Lackenby, O Hungnes, B Lina… - Emerging infectious …, 2009 - ncbi.nlm.nih.gov
In Europe, the 2007–08 winter season was dominated by influenza virus A (H1N1)
circulation through week 7, followed by influenza B virus from week 8 onward. Oseltamivir-resistant …